Prognostic value of the distance between the primary tumor and brainstem in the patients with locally advanced nasopharyngeal carcinoma by unknown
RESEARCH ARTICLE Open Access
Prognostic value of the distance between
the primary tumor and brainstem in the
patients with locally advanced
nasopharyngeal carcinoma
Yuxiang He1, Ying Wang1, Lin Shen1, Yajie Zhao1, Pengfei Cao1, Mingjun Lei1, Dengming Chen1, Tubao Yang2,
Liangfang Shen1* and Shousong Cao3
Abstract
Background: Brainstem dose limitations influence radiation dose reaching to tumor in the patients with locally-
advanced nasopharyngeal cancer (NPC).
Methods: A retrospective analysis of the prognostic value of the distance between the primary tumor and
brainstem (Dbs) in 358 patients with locally-advanced NPC after intensity-modulated radiation therapy (IMRT).
Receiver operating characteristic (ROC) curves were used to identify the cut-off value to analyze the impact of Dbs
on tumor dose coverage and prognosis.
Results: The three-year overall survival (OS), local relapse-free survival (LRFS), distant metastasis-free survival (DMFS),
and disease-free survival (DFS) were 88.8 vs. 78.4 % (P = 0.007), 96.5 vs. 91.1 % (P = 0.018), 87.8 vs. 79.3 % (P = 0.067),
and 84.1 vs. 69.6 % (P = 0.002) for the patients with the Dbs > 4.7 vs. ≤ 4.7 mm, respectively. ROC curves revealed
Dbs (4.7 mm) combined with American Joint Committee on Cancer (AJCC) T classification had a significantly better
prognostic value for OS (P < 0.05).
Conclusions: Dbs (≤4.7 mm) is an independent negative prognostic factor for OS/LRFS/DFS and enhances the
prognostic value of T classification in the patients with locally-advanced NPC.
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Background
The relationship of clear radiation dose–response has
been confirmed for the patients with nasopharyngeal
cancer (NPC). For example, Sze et al. [1] found that the
risk of local failure increases by 1 % with every 1 cm in-
crease in tumor volume. Additionally, Willner et al. [2]
observed a dose–response relationship between the
tumor volume and total radiation dose with regards to
local control in the patients with NPC, and found that if
the tumor volume doubled, an extra 5 Gy was required
for achieving equivalent local control, and even a total
dose of 72 Gy could not control the tumor with a
volume larger than 64 ml. However, these studies were
based on the patients with conventional radiotherapy.
A dose–response relationship still exists in the patients
with NPC with intensity-modulated radiation therapy
(IMRT), even though this new technique has significantly
improved tumor dose coverage [3, 4]. However, Ng et al.
[5] reported that the negative effect of the primary gross
tumor volume (GTV_P) on local failure-free survival
(LFFR) and disease-free survival (DFS) was outweighed by
the volume of under-dosing due to neighboring neuro-
logical structures. In their analysis of 444 patients in
whom dose tolerances were maintained for all critical
neurological organs at risk (OARs), most patients with T4
disease (some with T3) were under-dosed (<66.5 Gy), and
an under-dosed GTV_P volume of 3.4 cm3 was prognostic
factor for poor LFFS and DFS. The volume of the GTV_P
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that is under-dosed (<66.5 Gy) is mainly affected by the
neighboring neurological structures. Therefore, we
hypothesize that the distance between the primary tumor
and OARs may be a crucial factor for affecting survival
outcomes in the patients with NPC.
Of all OARs that influence the tumor dose coverage,
the brainstem is considered the most important factor,
as brainstem dose restriction outweighs tumor dose
coverage during the design of radiotherapy treatment
plans. According to the Radiation Therapy Oncology
Group (RTOG) 0225 [6] and 0615 [7] protocols, the
ideal maximal point dose should be less than 54 Gy for
the brainstem, and if the curative radiation dose cannot
be achieved due to the brainstem dose tolerance, an ac-
ceptable alternative dose is <60 Gy to 1 % of the brain-
stem volume. However, in the patients with locally
advanced NPC in whom the primary tumor is located
close to the brainstem, the radical radiotherapy with
IMRT cannot be delivered to some regions of the primary
tumor. Ng et al. [5] reported that good target dose cover-
age could be achieved for the patients with T1-3 disease.
However, under-dosed regions occurred in most patients
with T4 disease, with an average volume of 3.4 cm3 of the
primary tumor receiving <66.5 Gy (95 % of the prescribed
dose of 70 Gy), and under-dosing of regions of the pri-
mary tumor close to the brainstem may account for the
poor prognosis in the patients with T4 disease.
In the present study, we evaluated the impact of the
distance between the primary tumor and brainstem
(Dbs) on tumor dose coverage and investigated whether
the Dbs is a potential prognostic factor in the patients
with locally-advanced NPC receiving IMRT.
Methods
Patients
A total of 358 consecutive patients diagnosed with
locally-advanced NPC (T3/T4N0-3M0) who received
IMRT between August, 2008 and December, 2011 at
Xiangya Hospital of Central South University (Changsha,
Hunan province, China) were enrolled in this study. All
patients were diagnosed via nasopharyngeal biopsy and
nasopharyngeal and neck MRI examinations. In this
study, 346 out of 358 patients were eligible for survival
analysis due to the loss of 12 patients to follow-up. This
study was approved by the ethics committee of Xiangya
Hospital of Central South University (ID number: 2011
1086) and all participants have signed the informed con-
sent form. The clinical characteristics of the patients are
summarized in Table 1. The median age of the patients
was 46 year-old (range, 17–82 years).
Clinical staging
In addition to CT/MRI examination of the nasopharynx
and neck, the pre-treatment evaluation also included a
complete medical history, physical examination, chest X-
ray and/or CT (all patients with N3 disease underwent a
chest CT), B-ultrasound scan of the abdomen and neck,
bone scan and routine laboratory analysis. To reduce
subjectivity, all patients were restaged according to the
7th edition of the American Joint Committee on Cancer
(AJCC) Staging System for NPC; the MRI images for each
patient were independently reviewed by two senior clini-
cians from the Departments of Radiology and Oncology.
Definition of the Dbs
We re-contoured the brainstem for each patient accord-
ing to its anatomic location on CT–MRI fusion images.
The definition of brainstem-planning risk volume (PRV)
included the brainstem plus a 1 mm margin. Measure-
ment of the Dbs was performed as follows: the brain-
stem was serially extended by margins ranging from 1 to
10 mm to find the nearest point between the tumor and
brainstem (to avoid visual inaccuracy), and the vertical
distance between the closest edge of the primary tumor
and the surface of the brainstem was measured; the dis-
tance was recorded as 10 mm as the maximal value even
it exceeded 10 mm. Receiver operator characteristic
(ROC) curve analysis was used to calculate the cut-off
value for the Dbs with respect to overall survival (OS).
To determine the sacrificed volume of PGTVnx (SV-
PGTVnx): firstly, we defined a new PGTVnx in order to
eliminate the inconsistencies in expansion of the PGTV
boundary between patients, which included the GTVnx
and a 5 mm margin in all directions except for a 3 mm
margin in the posterior direction. Secondly, the volume
of overlap between the new PGTVnx and brainstem was
calculated to obtain the SV-PGTVnx (ml). Thirdly, the
values of radiation dose delivered in 1 cc (D1cc) and
dose received by 1 % of the volume (D1 %) for the
brainstem-PRV and the values of the maximum radiation
dose (Dmax), the mean radiation dose (Dmean), and the
minimum radiation dose (Dmin) of primary tumor, the
dose covering the 95 % PTV (D95 %), the volume receiv-
ing the 95 % prescribed dose (V95 %) for the new
PGTVnx were determined.
Radiotherapy
All patients underwent IMRT. The target volumes were
defined with reference to International Commission on
Radiation Units and Measurements (ICRU) reports No.
50 and No. 62. The primary tumor (GTVnx) and posi-
tive lymph nodes (GTVnd) were defined; the retrophar-
yngeal lymph nodes were included in the GTVnx. Two
clinical target volumes (CTVs) were defined, as de-
scribed in our previous study [8]. The corresponding
planning target volumes (PTVs) were generated by ex-
tending each CTV by 3 mm; the prescribed doses for
the PGTVnx (GTVnx + 3–5 mm margin) were 66.0–
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75.9 Gy; GTVnd, 69.96–72.6 Gy; PTV1, 59.4–64.0 Gy,
and PTV2, 50.0–54.0 Gy. The doses to the PTV2 were
administered over 28 fractions and other doses over 33
fractions. All patients were treated with simultaneous
modulated accelerated radiotherapy once a day for 5
days a week. The dose limits for the critical normal tis-
sue structures and plan evaluation were defined by Radi-
ation Therapy Oncology Group (RTOG) protocol 0225
[6] and the dose constrains are as follows: brainstem,
optic nerves, and chiasm ≤ 54 Gy or 1 % of the PTV ≤
60 Gy; spinal cord ≤ 45 Gy or 1 cc of the PTV ≤ 50 Gy;
temporal lobes ≤ 60 Gy or 1 % of the PTV ≤ 65 Gy. man-
dible and T-M joint ≤ 70 Gy or 1 cc of the PTV ≤ 75 Gy;
tongue < 55 Gy or 1 % of the PTV ≤ 65 Gy; inner/middle
ears mean dose < 50 Gy; glottic larynx mean dose <
45 Gy; parotid glands mean dose < 26 Gy (should be
achieved in at least one gland) or at least 20 cc of the
combined volume of both parotid glands < 20 Gy or at
least 50 % of the gland < 30 Gy (should be achieved in at
least one gland). Dose constraints for brainstem and
spinal cord have the higher priority than GTV or CTV
coverage while other normal structures will be consid-
ered lower priority than GTV or CTV coverage.
Chemotherapy
Chemotherapy was part of the treatment plan for all pa-
tients except 21 patients who were unwilling to receive or
could not tolerate chemotherapy. Neoadjuvant chemother-
apy was administered when the waiting time for radiother-
apy was longer than acceptable or to downsize bulky
tumors. At the end of radiotherapy, adjuvant chemotherapy
was administered to the patients with N2/N3 stage disease
and the patients with existing residual disease detected by
MRI or physical examination. Neoadjuvant chemotherapy
or adjuvant chemotherapy consisted of cisplatin plus 5-
fluorouracil or taxanes every 3 weeks for two or three
cycles. Concurrent chemotherapy consisted of 80 mg/m2
cisplatin every 3 weeks. There were 193 patients received
2 cycles and 153 patients received more than 3 cycles of
chemotherapy.
Follow-up
The follow-up methods included direct telephone calls
to the patients or their families; or hospital visits for the
patients. Follow-up was measured from the first day of
treatment to the last date of follow-up (January, 2015)
or the date of death. After radiotherapy, follow-up exam-
inations were conducted once every 3 months in the first
2 years, once every 6 months in years 2 to 5, and annu-
ally thereafter. Recurrence was defined as tumor recur-
rence after the tumor was undetectable for at least 1
month. The duration of OS was calculated from the day
of radiotherapy completion to the date of death or last
follow-up; LRFS, to the date of local recurrence; and
DFS, to the date of tumor recurrence, distant metastasis
or death.
Statistical analysis
All statistical analyses were performed using Statistical
Package for the Social Sciences version 17.0 (SPSS,
Chicago, IL, USA). The Dbs data were subjected to nor-
mality testing; then Mann–Whitney tests of non-
Table 1 The characteristics of the patients with locally-advanced nasopharyngeal carcinoma
Characteristic Group Number (%) P value
Dbs > 4.7 mm (n = 220) Dbs≤ 4.7 mm (n = 138)
Age (years) <50 143 (65.0) 89 (64.5) 0.922
≥50 77 (35.0) 49 (35.5)
Gender Male 159 (72.3) 96 (69.6) 0.582
Female 61 (27.7) 42 (30.4)
T classification T3 52 (23.6) 12 (8.7) <0.001
T4 168 (76.4) 126 (91.3)
N classification N0 44 (20.0) 22 (15.9) 0.514
N1 69 (31.4) 44 (31.9)
N2 67 (30.5) 51 (37.0)
N3 40 (18.2) 21 (15.2)
Histological type (WHO) I 13 (5.9) 12 (8.7) 0.314
II& III 207 (94.1) 126 (91.3)
Chemotherapy Yes 204 (92.7) 133 (96.4) 0.153
No 16 (7.3) 5 (3.6)
Prescribed dose <73.92 Gy 74 (33.6) 37 (26.8) 0.174
≥73.92 Gy 146 (66.4) 101 (73.2)
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parametric data were used to analyze the relationships
between the Dbs, T3/T4 disease, survival outcomes,
GTVnx Dmin, V95 % and D95 % in the different groups.
Actuarial rates were calculated using the Kaplan-Meier
method and compared with the log-rank test. Multivari-
ate analyses with the Cox proportional hazards model
were used to test for independent significance by back-
ward elimination of insignificant explanatory variables.
ROC curve analysis was used to compare prognostic
value. The criterion for statistical significance was set at




The median follow-up period for all patients was
45 months (range, 3–78 months). The characteristics of
the entire cohort of 358 patients with locally-advanced
NPC are summarized in Table 1. In total, 22 out of 346
patients developed local recurrence (6.36 %), 55 out of
346 patients developed distant metastasis (15.9 %), and 9
out of 346 patients developed recurrence plus distant
metastasis (2.6 %). There were 64 deaths among the 346
patients (18.5 %), of which 49 were due to tumor recur-
rence and metastasis, 10 were due to tumor-associated
complications, one was due to gastrointestinal bleeding
and four were due to unknown causes.
The distribution of Dbs in the patients with locally-advanced
NPC
The overall distribution of Dbs in the patients with locally
advanced NPC was a non-normal distribution (P > 0.10).
As shown in Fig. 1a and Table 2, the median Dbs was
8.3 mm (range, 0.5 to 10 mm) in the patients with T3 dis-
ease and 5.7 mm (range, −1.2 to 10 mm) in the patients
with T4 disease. The Mann–Whitney test suggested that
the median Dbs was significantly lower in the patients
with a T4 classification than the patients with T3
classification (P < 0.001). The median Dbs are 3.0 mm
(range, −1.2 to 10 mm) in the patients of GTVnx Dmin <
66Gy and 8.6 mm (range, 0.5 to 10 mm) in the patients of
GTVnx Dmin ≥ 66Gy (Fig. 1b and Table 2).
A small Dbs is associated with a reduced dose to the
primary tumor in the patients with locally-advanced NPC
The patients were divided into two groups according to
ROC analysis: Dbs ≤ 4.7 mm (220 patients) and Dbs >
4.7 mm (138 patients). The difference of prescribed radi-
ation doses to the PGTVnx for the two groups was not
statistically significant (73.6 vs 73.5 Gy, P > 0.05), how-
ever, the D95 % and V95 % values of the PGTVnx were
significantly lower in the patients of Dbs ≤ 4.7 mm than
in the patients of Dbs > 4.7 mm (median D95 %: 70.0 vs.
73.7 Gy, P < 0.001, and median V95 %: 95.2 vs.
99.8 %, P < 0.001, respectively), as shown in Fig. 2a and 2b
and Table 3. These data indicate that the D95 % and
V95 % decrease as the Dbs becomes smaller.
As shown in Table 4, the patients with a smaller Dbs
(≤4.7 mm) had a larger GTV-P, a larger SV- PGTVnx,
and the lower values of Dmin, D95 %, and V95 % for the
PGTVnx compared to the patients with a larger Dbs
(>4.7 mm). However, the differences of these parameters
Fig. 1 The distribution of the distance between the primary
tumor and brainstem (Dbs) in the patients with locally-advanced
nasopharyngeal carcinoma stratified by T classification (a) and
GTVnx Dmin (b)
Table 2 The distance from the primary tumor to the brainstem
(Dbs) in the patients with locally-advanced nasopharyngeal
carcinoma
Dbs (mm) T stage (7th AJCC) GTVnx Dmin
T3 (n = 64) T4 (n = 294) ≥66Gy <66Gy
Mean ± SD 8.3 ± 2.7 5.94 ± 3.6 8.6 ± 0.15 3.0 ± 0.19
Median 10 5.7 10 3.0
Range 0.5–10 −1.2–10 0.2–10 −1.2–10
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were much smaller between the patients with T3 and
the patients with T4 classifications. The data suggest that
the Dbs has a greater influence on the smaller dose to
the primary tumor than that of T classification. These
radiation doses of Dmax, D1 %, D1cc, D1/3, Dmean
were not significantly different for the brainstem be-
tween the patients with a small and large Dbs, nor with
T3 and T4 classifications (Table 4).
The data in Fig. 2c illustrate the relationship between
the Dbs and radiation dose to the primary tumor. When
the tumor was near the brainstem, some of the PGTVnx
and GTVnx laid outside of the 60 Gy isodose lines. The
minimum radiation dose of SV-PGTVnx (the orange
filled areas) was lower than 45 Gy.
Prognostic value of the Dbs in the patients with locally-
advanced NPC
The data in Fig. 3 show the survival curves of two
groups of patients with different Dbs, SV-PGTVnx and
GTVnx Dmin. The rates of 3-year OS, LRFS, DMFS and
DFS for the two groups of patients stratified by Dbs
(>4.7 mm or ≤ 4.7 mm) were 88.8 vs. 78.4 % (P = 0.007),
96.5 vs. 91.1 % (P = 0.018), 87.8 vs. 79.3 % (P = 0.067),
and 84.1 vs. 69.6 % (P = 0.002), respectively. These were
significantly different between the two groups, except
DMFS (Fig. 3a-d, Table 5).
The rates of 3-year OS, LRFS, DMFS and DFS for the
two groups of patients stratified by SV-PGTVnx (≤0 ml
or > 0 ml) were 87.8 vs. 77.5 % (P = 0.005), 96.5 vs. 89.5 %
(P = 0.004), 87.7 vs. 77.9 % (P = 0.047), and 83.3 vs. 66.9 %
(P < 0.001), respectively. These were significantly different
between the two groups (Fig. 3e-h, Table 5).
The rates of 3-year OS, LRFS, DMFS and DFS for the
two groups of patients stratified by GTVnx Dmin (≥66Gy
or < 66Gy) were 89.6 vs. 77.8 % (P = 0.002), 96.3 vs. 91.7 %
(P = 0.03), 89.4 vs. 77.4 % (P = 0.016), and 84.6 vs. 69.5 %
(P = 0.002), respectively. These were significantly different
between the two groups (Fig. 3i-l, Table 5).
The univariate analysis suggests that the factors influen-
cing the 3-year OS are age (P = 0.003), N-stage (P = 0.003),
overall stage (P = 0.041), GTVnx Dmin (P = 0.002), and
Dbs (P = 0.007), respectively. The factors influencing LFRS
are age (P < 0.001), GTVnx Dmin (P = 0.003), and Dbs
(P = 0.018), respectively. The factors influencing the 3-year
















Fig. 2 Relationship of the distance between the primary tumor and
brainstem (Dbs) and PGTVnx V95 % (a); PGTVnx V95 % (b); and the
radiation dose to GTVnx (c) of the patients with locally-advanced
NPC. The color-filled areas represent the target volumes: GTVnx (red);
PGTVnx (blue); brainstem (yellow); and sacrificed volume of PGTVnx
(SV-PGTVnx, orange)
Table 3 D95 % and V95 % of the PGTVnx for the patients with locally-advanced nasopharyngeal carcinoma stratified by the distance
from the primary tumor to the brain stem (Dbs)
D95 %/V95 % D95 % (Gy) Total V95 % (%) Total
Dbs≤ 4.7 Dbs > 4.7 Dbs≤ 4.7 Dbs > 4.7
Mean ± SD 69.0 ± 4.9 73.1 ± 2.0 71.5 ± 4.0 94.8 ± 3.2 99.1 ± 1.6 97.5 ± 3.2
Median 70.0 73.7 72.3 95.2 99.8 98.8
Range 49.9–80.5 64.9–81.0 49.9–81.0 84.4–99.8 90–100 84.4–100
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Table 4 Radiation doses to the PGTVnx and brain stem for the patients with locally-advanced nasopharyngeal carcinoma stratified
by T classification and the distance from the primary tumor to the brain stem (Dbs)
Mean (range) Dbs≤ 4.7 mm Dbs > 4.7 mm 7th AJCC T3 7th AJCC T4
Tumor volume
GTV-P (ml) 63.0 (16.5–204.8) 33.6 (5.9–164.0) 25.3 (6.3–73) 49.2 (5.9–204.8)
SV-PGTVnx (ml) 0.52 (0–12.4) 0.002 (0–0.2) 0.02 (0–0.44) 0.24 (0–12.4)
PGTVnx
Dmin (Gy) 46.4 (21.9–66.6) 63.1 (21.7–74) 62.5 (38.6–73.6) 55.4 (21.7–74)
Dmean (Gy) 75.4 (65.6–83.9) 75.8 (67.6–84.1) 76.2 (71.0–81.1) 75.6 (65.6–84.1)
Dmax (Gy) 80.3 (69.5–88.7) 79.3 (70.9–88.8) 79.8 (76–84.1) 79.7 (69.5–88.8)
D95 % (Gy) 69.0 (49.9–80.5) 73.1 (64.9–81) 72.8 (57.9–78.4) 71.2 (49.9–81)
V95 % (Gy) 94.8 (84.4–98.8) 99.1 (90–100) 98.8 (90.2–100) 97.2 (84.4–100)
Brain stem
Dmax (Gy) 54.1 (45.1–68.4) 51.8 (41.7–68.8) 50.9 (42.7–56.3) 52.5 (41.7–68.8)
D1 % 49.1 (38.8–59) 46.7 (34.8–58.6) 46.3 (34.8–50.6) 47.9 (36.9–59.9)
D1cc (Gy) 47.6 (36.7–56.7) 45.3 (35.4–52.4) 44.9 (35.4–49.8) 46.4 (35.7–56.7)
D1/3 (Gy) 39.9 (28.7–51.2) 37.2 (22.8–53.8) 37.4 (22.8–53.8) 38.4 (26.1–51.2)
Dmean (Gy) 36.4 (25.8–49.8) 31.6 (19.7–41.7) 31.6 (19.7–37.5) 33.8 (21.1–49.8)
SV-PGTVnx: sacrificed volume of the PGTVnx
Fig. 3 Survival curves of the patients with locally-advanced NPC stratified by the distance between the primary tumor and brainstem (Dbs >
4.7 mm or ≤ 4.7 mm, a-d); the sacrificed volume of PGTVnx (SV-PGTVnx≤ 0 ml or > 0 ml, e-h); and the minimum radiation dose of primary tumor
(GTVnx Dmin≥ 66Gy or < 66 Gy, i-l)
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stage (P = 0.009), and GTVnx Dmin (P = 0.016), re-
spectively. The factors influencing DFS are age (P = 0.015),
N-stage (P = 0.018), T-stage (P = 0.033), overall stage
(P = 0.014), GTVnx Dmin (P = 0.002), and Dbs (P = 0.002),
respectively. However, chemotherapy and prescribed radi-
ation dose are not the factors for significantly influencing
the OS, LFRS, DMFS or DFS (Table 5).
The following parameters were included in the Cox
proportional hazards model with backward elimination:
Dbs (>4.7 vs. ≤ 4.7 mm), age (<50 vs. ≥ 50 years), gender
(female vs. male), World Health Organization (WHO)
histological grade (Type II & III vs. Type I), T classification
(T3 vs. T4), N classification (N0 vs. N1 vs. N2 vs. N3),
chemotherapy (with vs. without) and radiation doses
(>73.92 vs. ≤ 73.92 Gy). As the results shown in Table 6,
Dbs ≤ 4.7 mm was a negative independent prognostic
factor for OS (HR = 1.929; P = 0.01), LRFS (HR = 2.84;
P = 0.044), and DFS (HR= 1.977; P = 0.002), but not for
DMFS (HR= 1.479; P = 0.156). Additionally, these parame-
ters were identified as independent prognostic factors: age
and N classification for OS; age for LRFS, N classification
for DMFS; and age and N classification for DFS (Table 6).
Predictive value of Dbs combined with T classification in
the patients with locally-advanced NPC
ROC curve analysis was used to assess the prognostic
value of T classification alone or in combination of T
classification with Dbs (Fig. 4). The combination of T
classification with Dbs had a significant prognostic value
for OS (AUC = 0.602; P = 0.011) but not with T classifica-
tion alone (AUC = 0.547; P = 0.239).
Table 5 Univariate analysis of prognostic factors in the patients with locally-advanced nasopharyngeal carcinoma receiving IMRT
Variable No.# N = 346 3-year OS (%) p-value 3-year LRFS (%) p-value 3-year DMFS (%) p-value 3-year DFS (%) p-value
Age 0.003 <0.001 0.305 0.015
<50 y 225 87.8 97.7 86.6 82.1
≥50 y 121 79.0 88.1 81.5 71.6
N-stage 0.003 0.904 <0.001 0.018
N0 63 92.0 93.5 90.1 85.6
N1 110 89.0 94 89.3 81.5
N2 113 87.4 94.4 86.9 78.5
N3 60 69.6 96.3 65.9 64.9
T-stage 0.111 0.667 0.035 0.033
T3 59 89.6 93.2 93.2 88.1
T4 287 83.7 94.7 82.8 76.4
Overall stage 0.041 0.524 0.009 0.014
III 53 92.3 92.5 96.2 90.6
IV 293 83.3 94.8 82.4 76.2
Chemotherapy 0.386 0.242 0.921 0.374
Yes 327 85.1 94.8 84.7 79
No 19 78.9 88.4 82.6 68.4
Cycles of chemotherapy 0.841 0.853 0.835 0.988
<3 193 84.7 94.4 85.2 79.1
≥3 153 84.8 94.5 87.0 77.6
Prescribed dose 0.926 0.509 0.832 0.981
≤73.92 Gy 311 84.7 94.2 84.5 78.0
>73.92 Gy 35 85.3 96.9 85.2 82.7
GTVnx Dmin 0.002 0.03 0.016 0.002
<66 Gy 142 77.8 91.7 77.4 69.6
≥66 Gy 204 89.6 96.3 89.4 84.6
Dbs (mm) 0.007 0.018 0.067 0.002
≤4.7 136 78.4 91.1 79.3 69.6
>4.7 210 88.8 96.5 87.8 84.1
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Discussion
The present study demonstrated that Dbs is an inde-
pendent prognostic factor for OS, LRFS and DFS in the
patients with locally-advanced NPC receiving IMRT, and
the small Dbs hindered the improvement of the Dmin of
tumor leading to poor prognosis. Compared to conven-
tional radiotherapy, IMRT can improve target volume
conformation while reducing the dose to the OARs.
However, for the patients with locally-advanced NPC,
the tumor lies close to the neighboring OARs, so it is
difficult to achieve the desired dose distribution, even
with IMRT [9]. In the study by Ng et al. [5], the average
lowest dose for the GTV in T4 disease was 53.5 Gy
(range, 29.9 to 70.1 Gy) and the average D95 % was
67 Gy (range, 55.5 to 71.4 Gy), which were far below the
radical radiation dose required for T4 disease [2]. Chau
et al. [10] analyzed IMRT dose distributions in the pa-
tients with T3-4 NPC, and reported the average Dmin to
the GTV increased from 33.7 Gy for 2D-CRT to 62.6 Gy
for IMRT, and the average D95 % increased from
57.1 Gy for 2D-CRT to 67 Gy for IMRT. However, it
failed to achieve the tumor desirable doses and normal
tissue dose limitations when the tumor was located close
to OARs.
Abbasi et al. [11] identified the main factors affecting
the tumor V95 % including advanced T classification,
intracranial tumor invasion and a tumor volume greater
than 200 cm3. The data in Fig. 2 and Tables 3 and 4 of
the present study showed that at an equivalent pre-
scribed dose, the values of average D95 %, V95 %, and
PGTVnx Dmin were 70.0 Gy, 95.2 % and 46.4 Gy for
the patients with a small Dbs (≤4.7 mm) and 73.8 Gy,
99.8 % and 63.1 Gy for the patients with a large Dbs
(>4.7 mm), respectively. The data indicate that appropriate
target dose coverage can be achieved in the patients with
a large Dbs, but not in the patients with a small Dbs
(Table 4). However, the median Dbs was only 3.0 mm in
the patients with GTVnx Dmin < 66 Gy, which is much
smaller than in the patients with GTVnx Dmin ≥ 66 Gy of
8.6 mm (Fig. 1b and Table 2). Therefore, the Dbs hinders
further improvement in radiation dose for IMRT in the
patients with locally-advanced NPC.











OS Age 0.845 0.252 0.001 2.328 1.422 3.812
N classification 0.431 0.133 0.001 1.539 1.185 1.999
Dbs 0.657 0.253 0.010 1.929 1.174 3.170
T classification 0.383 0.438 0.381 1.467 0.622 3.460
LRFS Age 1.802 0.578 0.002 6.061 1.953 18.804
Dbs 1.044 0.518 0.044 2.840 1.030 7.831
T classification 0.103 0.767 0.894 1.108 0.246 4.986
DMFS N classification 0.451 0.145 0.002 1.570 1.182 2.085
Dbs 0.391 0.276 0.156 1.479 0.842 6.638
T classification 0.958 0.520 0.066 2.606 0.940 7.225
DFS Age 0.600 0.225 0.008 1.822 1.172 2.835
N classification 0.344 0.119 0.004 1.411 1.118 1.781
Dbs 0.682 0.225 0.002 1.977 1.273 3.070
T classification 0.576 0.403 0.153 1.780 0.808 3.920
Note: Disease staging was according to the 7th edition of the AJCC/UICC staging system
The following parameters were included in the Cox proportional hazards model with backward elimination: Dbs (>4.7 mm vs. ≤ 4.7 mm), age (<50 years vs. ≥
50 years), gender (female vs. male), World Health Organization (WHO) histological grade (Type II & III vs. Type I), T classification (T3 vs. T4), N classification (N0 vs.
N1 vs. N2 vs. N3), chemotherapy (with vs. without), and radiation doses (>73.92 Gy vs. ≤ 73.92 Gy)
Fig. 4 Receiver operator characteristic (ROC) curves of OS of the
patients with locally-advanced NPC with T classification alone or in
combination of T classification with Dbs
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The reason for us to choose Dbs 4.7 mm as the cut-off
value is from ROC curve analysis. The determination of
ROC cut-off value is always complied with the principle
of maximization in the sensitivity plus (1-specificity) or
the maximization of the sum of the true positive rate
and false negative rate, which is the optimal cut-off
value. Therefore, we calculated the cut-off value of Dbs
as 4.7 mm by ROC curve analysis. We initially investi-
gated three distances: 1) Dbs > 5 mm ; 2) Dbs > 2 mm
but ≤ 5 mm; and 3) Dbs ≤ 2 mm before we chose ROC
curve analysis to find the optimal cut-off value. The re-
sults showed that the 3-year OS, LRFS, DMFS, and DFS
were 88.5 vs 85.6 vs 68.5 % (P = 0.003),96.2 vs 92.5 vs
88.9 % (P = 0.033), 87.5 vs 86.1 vs 68.7 % (P = 0.012),
and 84.0 vs 78.6 vs 56.9 % (P < 0.001) for Dbs >
5 mm, Dbs > 2 mm but ≤ 5 mm; and Dbs ≤ 2 mm, re-
spectively. However, there are not the optimal cut-off
values for comparison.
An insufficient dose of radiation is associated with re-
duced local control and a poor prognosis. For example,
Ng et al. [5] reported that a bulky primary tumor was re-
lated to poorer OS; however, if a satisfactory dose of ra-
diation (>70 Gy) was delivered to large tumors, the same
treatment outcomes could be achieved similarly to small
tumors. In addition, the effect of GTV_P volume on
LFFR and DFS was outweighed by the degree of under-
dosing. In our study, most patients had a prescribed
dose of approximately 73.92 Gy and a D95 % of
70.22 Gy. The tumor volume under-dosed (<70.22 Gy)
was mainly affected by the Dbs and limitation of the
brainstem. Clinically, the dose priorities for the primary
tumor and brainstem vary widely between different can-
cer centers and/or different physics technicians and on-
cologists. The Cancer hospital of Chinese Academy of
Medical Sciences reported a brainstem Dmax of up to
80.3 Gy in the patients with T4 disease [12], and sug-
gested that one possible strategy to treat advanced T4
disease is to drop the dose constraints for selected
neurologic structures. However, the risk of radioactive
brainstem injury was not mentioned in the report.
Therefore, it is difficult to define the most appropriate
dose tolerances for neurologic structures such as the
brainstem, and long term follow-up studies are needed
to monitor the complications caused by radiation. In the
present study, the SV-PGTVnx and the Dbs were coun-
terpart to an under-dosed volume as reported by Ng et
al., but were more intuitively and conveniently due to
the tumor closed to brainstem in the patients so the
lower Dmin could be delivered into the tumor (Table 4).
To our knowledge, no study has been reported for
Dbs affecting prognosis in the patients with NPC. In the
present study, we had demonstrated that the 3-year OS,
LRFS, DMFS and DFS was better for the patients with
Dbs > 4.7 mm than the patients with Dbs ≤ 4.7 mm (P <
0.05 except for DMFS), and for the patients with SV-
PGTVnx ≤ 0 ml than the patients with SV-PGTVnx >
0 ml (P < 0.05). The results are consistent with the re-
port by Ng et al. [5], which they showed that the 5 year
LRFS, DFS, and OS were 90.4 vs 54.3 %, 70.6 vs 26.0 %,
and 76.8 vs 53.2 % (p < 0.001) for the patients with
GTV-P 66.5 Gy < 3.4 cm3 and the patients with GTV-P
66.5 Gy ≥ 3.4 cm3, respectively. Their results indicate
that the volume of tumor under-dosed (<66.5 Gy) had a
significantly impact on the prognosis of the patients with
NPC. The results suggest that the volume of tumor
under-dosed (<66.5 Gy) was not only related to a short
Dbs, but also to the dose tolerances for the optic nerve,
optic chiasm and temporal lobe. Therefore, the exact
tumor regions where insufficient dosing occurred are
unknown. However, our study focused on the distance
between the primary tumor and brainstem, as we
followed the principle of prioritizing life-saving treat-
ment during dose assessment, with priority was given to
protection of the brainstem and spinal cord over treat-
ment of the primary tumor, and the dose to the tumor
outweighing the tolerances for the optic nerve, optic chi-
asm and temporal lobe. For advanced disease, we do not
reduce radiation dose to tumor during treatment, even if
the patient may bear an increased probability of
radiotherapy-induced vision loss, blindness or temporal
lobe damage. Based on such principle, only the brain-
stem and/or spinal cord are the key factor for the selec-
tion of radiation dose, while the optic nerve and others
are less weighed compared to tumor treatment.
The reason for Dbs as an independent prognostic fac-
tor for OS, LRFS and DFS, but not for DMFS in the pa-
tients with locally-advanced NPC may be due to the fact
that a short Dbs reduces local control, whereas DMFS is
affected more by N classification, tumor volume, and
biological characteristics of the tumor. Therefore, Dbs
has less influence on DMFS than other parameters of
survival outcomes.
SV-PGTVnx had a greater effect on the distribution
of the isodose curves than that of Dbs. Moreover, we
could not obtain the value of SV-PGTVnx in spite of
Dbs can be obtained before treatment, which may
affect us to make an appropriate decision when a pa-
tient needs an induction of chemotherapy to shrink
the tumor in order to avoid brainstem injure. In the
present study, we had demonstrates that the lower ra-
diation dose of tumor had a worse treatment outcome
(Fig. 3i-l) and a lower radiation doses may be due to
a closer Dbs (Fig. 1b and Table 2). Moreover, age and
N stage were independent prognostic factor for OS,
LRFS and DFS (Tables 5 and 6). It had been proved that
the older age had the worse prognosis and N staging
affected the prognosis of the patients with NPC by Meta
analyses [13, 14].
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With advance treatment with comprehensive IMRT
for the patients with NPC in recent years, the prognosis
for the patients with locally-advanced NPC has been im-
proved significantly, especially the local control rate.
Many studies have found that the T classification had no
predictive and prognostic values for local control and
OS, whereas tumor volume was an important factor for
prognosis in the patients with NPC [1, 2, 4, 15–20]. In
the present study, the patients with a large Dbs also had
a large primary tumor volume (GTV-P). As shown in
Table 4, the mean volume of the GTV-P was 63.0 (16.5–
204.8) ml for the patients with Dbs ≤ 4.7 mm and 33.6
(5.9–164.0) ml for the patients with the Dbs > 4.7 mm,
respectively. In addition, Dbs affects the progression of
patients with NPC mainly through lowering the radi-
ation dose in the tumor and increasing the dose on the
surrounding normal tissues. This is different with tumor
volume affecting the progression of patients due to large
tumor burden and increase of tumor Hypoxia.
Experience from the group of Hong Kong [21] indicated
that dose escalation above 66 Gy in IMRT-based therapy
was a significant determinant of progression-free survival
and DMFS for the patients with an advanced T classifica-
tion. This finding was also confirmed by our study
(Fig. 3i-l). A small Dbs of patient is not only related to the
bulky tumor volume, but also to lower delivered dose to
the tumor, it is therefore bound to further influence prog-
nosis. However, so far there is no report on how the dis-
tance between the primary tumor and OARs may affect
prognosis. Our study has demonstrated that the Dbs is a
very important independent prognostic factor in the pa-
tients with locally-advanced NPC. Additionally, the prog-
nostic value significant improved when combined Dbs
with T-stage (Fig. 4).
The limitations of our studies are the relatively short
follow-up period in which radiation-induced brainstem in-
jury and other late complications could not be assessed.
Additionally, the number of cases is too small for T3
stage, and it’s a retrospective study. It is worth to further
prospective study to elaborate the different effect of Dbs
on the tumor dose and associated complications to find
the appropriate individualized prescribed dose of future
IMRT in the patients with NPC with different Dbs.
Conclusions
In locally advanced NPC, Dbs (≤ 4.7 mm) is an inde-
pendent negative prognostic factor for OS/LRFS/DFS
and enhances the prognostic value of T classification.
The findings may improve clinic stage of NPC and en-
able individualized cancer therapy according to the dif-
ferent tumor-brainstem distance.
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